{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:23:08Z","timestamp":1764958988590,"version":"3.46.0"},"reference-count":26,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Systemic therapy is the mainstay of treatment in inoperable cholangiocarcinoma (CCA). The aim of this study was to evaluate the overall survival (OS), progression-free survival (PFS), recurrence patterns, and the association between biliary complications and OS in patients with inoperable, localized cholangiocarcinoma treated with radiotherapy (RT) alone. Records of patients treated between 2004 and 2022 who received a minimum of 32.5 Gy BED10 were retrospectively reviewed. Survival was estimated using the Kaplan\u2013Meier method, and prognostic factors were assessed using univariate and multivariable analyses. A total of 56 patients (median age 67.5) were included, most of whom had intrahepatic (78.6%) CCA, and most of whom received SBRT (76.8%). The median dose was 36 Gy (BED 55 Gy), and the median OS and PFS were 20 months and 10 months, respectively. One-year local control was 92.1% and the primary site of progression was intrahepatic (64.9%). On univariate analyses, pre-radiation biliary obstruction, elevated baseline CA 19-9, larger tumor size, and age were associated with worse outcomes; on multivariable analysis, only lesion size was prognostic. Biliary complications were associated with inferior OS. These findings highlight the high intrahepatic out-of-field failure rates and suggest the incorporation of biliary-event-free survival as a clinically relevant endpoint.<\/jats:p>","DOI":"10.3390\/curroncol32120676","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:35:17Z","timestamp":1764956117000},"page":"676","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultra- and Moderately Hypofractionated Radiotherapy for Inoperable Cholangiocarcinoma: A Single-Institution Retrospective Analysis"],"prefix":"10.3390","volume":"32","author":[{"given":"Saheli","family":"Saha","sequence":"first","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4638-3059","authenticated-orcid":false,"given":"Cameron","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui Amy","family":"Liu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-6563","authenticated-orcid":false,"given":"Michael","family":"Yan","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Ann","family":"Dawson","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Hosni","family":"Abdalaty","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Lukovic","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7210-3330","authenticated-orcid":false,"given":"Rebecca","family":"Wong","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2734-7090","authenticated-orcid":false,"given":"Aisling","family":"Barry","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kim","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaya","family":"Shwaartz","sequence":"additional","affiliation":[{"name":"Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-794X","authenticated-orcid":false,"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13304-020-00750-5","article-title":"Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma","volume":"72","author":"Lleo","year":"2020","journal-title":"Updates Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000516880","article-title":"Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis","volume":"10","author":"Yu","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2025.43.16_suppl.4007","article-title":"A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB)","volume":"43","author":"Engineer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","article-title":"Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: A meta-analysis and systematic review","volume":"195","author":"Lee","year":"2019","journal-title":"Strahlenther. Onkol."},{"key":"ref_8","unstructured":"(2024, January 01). NRG-GI001, Available online: https:\/\/cdn.clinicaltrials.gov\/large-docs\/42\/NCT02200042\/Prot_SAP_000.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00423-017-1591-8","article-title":"Portal vein embolization in extended liver resection","volume":"402","author":"Narula","year":"2017","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.21873\/cdp.10153","article-title":"Efficacy and Safety of External-beam Radiation Therapy for Unresectable Primary or Local Recurrent Cholangiocarcinoma","volume":"2","author":"Murakami","year":"2022","journal-title":"Cancer Diagn. Progn."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3857\/roj.2014.32.3.163","article-title":"Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma","volume":"32","author":"Jung","year":"2014","journal-title":"Radiat. Oncol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2011.05.016","article-title":"Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience","volume":"99","author":"Polistina","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","article-title":"Stereotactic body radiotherapy for unresectable cholangiocarcinoma","volume":"94","author":"Kopek","year":"2010","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1245\/s10434-019-08142-9","article-title":"Hypofractionated Radiation Therapy for Unresectable\/Locally Recurrent Intrahepatic Cholangiocarcinoma","volume":"27","author":"Smart","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.7150\/jca.13032","article-title":"Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma","volume":"6","author":"Mahadevan","year":"2015","journal-title":"J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2018.11.015","article-title":"Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma","volume":"132","author":"Brunner","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gkika, E., Hallauer, L., Kirste, S., Adebahr, S., Bartl, N., Neeff, H.P., Fritsch, R., Brass, V., Nestle, U., and Grosu, A.L. (2017). Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3788-1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-717X-7-67","article-title":"Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma","volume":"7","author":"Barney","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.adro.2019.08.003","article-title":"Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation","volume":"5","author":"Kozak","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2010.03.013","article-title":"Stereotactic fractionated radiotherapy for Klatskin tumours","volume":"95","author":"Momm","year":"2010","journal-title":"Radiother. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","article-title":"Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial","volume":"42","author":"Hawkins","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhu, M., Jin, M., Zhao, X., Shen, S., Chen, Y., Xiao, H., Wei, G., He, Q., Li, B., and Peng, Z. (2024). Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med., 22.","DOI":"10.1186\/s12916-024-03381-4"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/676\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:20:00Z","timestamp":1764958800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["curroncol32120676"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32120676","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}